Companies Dominating the Bile Acid Sequestrants Market
- Pfizer Inc.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca Plc
- Ecogene
- Novartis International AG
- Sanofi S.A.
- Amgen Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- GlaxoSmithKline plc.
- Octapharma AG
Browse Key Market Insights with Data Illustration:
In the News
- Pfizer Inc. released top-line outcomes from the Phase 2b study of vupanorsen (PF-07285557), an investigational treatment being formulated for possible symptoms in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen accomplished a statistically substantial limiting of non- HDL-C, triglycerides, and other lipoproteins associated with cardiovascular disease.
- The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has obtained the Biologics License Application (BLA) for nirsevimab for the prohibition of respiratory syncytial virus (RSV) lower respiratory tract disease in toddlers and infants coming or during their first RSV season and for kids up to 24 months of age who stay exposed to acute RSV disease through their second RSV season.
